<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03195478</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-672</org_study_id>
    <nct_id>NCT03195478</nct_id>
  </id_info>
  <brief_title>Study of Nivolumab in Combination With Ipilimumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of Nivolumab (BMS-936558) in Combination With Ipilimumab (BMS-734016) in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to Evaluate Safety and Effectiveness of Nivolumab in Combination With Ipilimumab in
      Chinese Patients With Previously Treated Late-Stage Cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2017</start_date>
  <completion_date type="Anticipated">June 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 26, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of Number and percent of all treated subjects that experience Adverse Events (AEs)</measure>
    <time_frame>Approximately 68 weeks</time_frame>
    <description>Measured by number of patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of Number and percent of all treated subjects that experience serious adverse events (SAEs)</measure>
    <time_frame>Approximately 68 weeks</time_frame>
    <description>Measured by number of patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of Number and percent of all treated subjects that experience AEs leading to discontinuation</measure>
    <time_frame>Approximately 68 weeks</time_frame>
    <description>Measured by number of patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of Number and percent of all treated subjects that experience AEs leading to death</measure>
    <time_frame>Approximately 68 weeks</time_frame>
    <description>Measured by number of patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of Number and percent of subjects with clinical laboratory abnormalities</measure>
    <time_frame>Approximately 68 weeks</time_frame>
    <description>Measured by number of patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax)</measure>
    <time_frame>Approximately 68 weeks</time_frame>
    <description>Measured using serum concentration versus time data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax)</measure>
    <time_frame>Approximately 68 weeks</time_frame>
    <description>Measured using serum concentration versus time data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to the last time of the last quantifiable concentration (AUC[0-T])</measure>
    <time_frame>Approximately 68 weeks</time_frame>
    <description>Measured using serum concentration versus time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval (AUC[TAU])</measure>
    <time_frame>Approximately 68 weeks</time_frame>
    <description>Measured using serum concentration versus time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration achieved at the end of study drug infusion (Ceoinf)</measure>
    <time_frame>Approximately 68 weeks</time_frame>
    <description>Measured using serum concentration data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentration at the end of dosing interval (Ctrough)</measure>
    <time_frame>Approximately 68 weeks</time_frame>
    <description>Measured using serum concentration data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at the end of dosing interval (Ctau)</measure>
    <time_frame>Approximately 68 weeks</time_frame>
    <description>Measured using serum concentration data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug Antibody (ADA)</measure>
    <time_frame>Approximately 68 weeks</time_frame>
    <description>Measured by immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR) by investigator using Response Evaluation Criteria in Solid Tumor (RECIST v1.1)</measure>
    <time_frame>Approximately 68 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Approximately 68 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival Rate (PFSR) at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Nivo/Ipi Combination Therapy A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified Dose of Nivolumab and Ipilimumab on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivo/Ipi Combination Therapy B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified Dose of Nivolumab and Ipilimumab Combination Therapy on specified days followed by specified dose of Nivolumab Monotherapy on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivo/Ipi Combination Therapy C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified Dose of Nivolumab and Ipilimumab Combination Therapy on specified days followed by specified dose of Nivolumab Monotherapy on specified days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified dose of Nivolumab on specified days.</description>
    <arm_group_label>Nivo/Ipi Combination Therapy A</arm_group_label>
    <arm_group_label>Nivo/Ipi Combination Therapy B</arm_group_label>
    <arm_group_label>Nivo/Ipi Combination Therapy C</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Specified Dose of Ipilimumab on specified days</description>
    <arm_group_label>Nivo/Ipi Combination Therapy A</arm_group_label>
    <arm_group_label>Nivo/Ipi Combination Therapy B</arm_group_label>
    <arm_group_label>Nivo/Ipi Combination Therapy C</arm_group_label>
    <other_name>BMS-734016</other_name>
    <other_name>Yervoy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          1. Mainland Chinese subjects with advanced or recurrent solid tumors.

          2. One prior anti-cancer therapy that did not work or documented refusal to receive
             chemotherapy or biological therapy.

        Exclusion Criteria:

          1. Cancer that has spread to the brain or central nervous system unless it has been
             adequately treated . In addition, either no longer receiving corticosteroids, or on a
             stable or decreasing dose of no more than 10 mg daily prednisone (or equivalent).

          2. Subjects with carcinomatous meningitis

          3. Active, known or suspected autoimmune disease or infection

          4. Positive blood screen for chronic infection of hepatitis B or hepatitis C

          5. Prior immuno-oncology therapy

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Educational Resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

